Mack Roach III, MD

Mack Roach III, MD

Professor and Chair, Department of Radiation Oncology, and Professor, Department of Urology, UCSF

Phone: (415) 353-9807 (appts)
Box 1708, UCSF
San Francisco, CA 94143-1708

View on UCSF Profiles

Cancer Center Membership

Program Member » Prostate Cancer» Cancer Control


Morehouse College, Atlanta, GA, BS, 1975, Physics
Stanford University School of Medicine, Stanford,CA, MD, 1979, Medicine
University of California San Francisco, Fellow, 1981-83, Med Oncology
Stanford University School of Medicine, Stanford,CA, Resident, 1984-87, Radiation Oncology

Professional Experience

  • 1987-1988
    Acting Chief, Radiation Oncology Service, VA Medical Center, Martinez, CA
  • 1988-1990
    Chief, Radiation Oncology Service, VA Medical Center, Martinez, CA
  • 1990-1994
    Assistant Professor, Department of Radiation Oncology, UCSF
  • 1994-2000
    Associate Professor, Department of Radiation Oncology, UCSF
  • 2000-present
    Professor, Department of Radiation Oncology & Urology, UCSF
  • 2003-2007
    Vice Chair, Department of Radiation Oncology, UCSF
  • 2006-2007
    Interim Chair, Department of Radiation Oncology
  • 2007-present
    Chair, Department of Radiation Oncology

Honors & Awards

  • 1980-1981
    Outstanding Intern of the Year (Charles R. Drew Award)
  • 1981-1982
    Fellow of the American Cancer Society
  • 1994
    UCSF Health Net Wellness Award
  • 1994-1997
    American Cancer Society Career Development Award
  • 1996-97; 1997-98; 2001-02
    "The Best Doctors in America"
  • 2002
    Fellow, American College of Radiology
  • 2002-05
    President, John Hale Medical Society
  • 2005
    10 Most Influential African Americans in the Bay Area (Healthcare)

Selected Publications

  1. Pisansky TM, Suman VJ, Roach M, Sandler HM. Reporting of results in DART01/05 GICOR. Lancet Oncol. 2015 Jun; 16(6):e258.
    View on PubMed
  2. Hsu CC, Paciorek AT, Cooperberg MR, Roach M, Hsu IC, Carroll PR. Postoperative radiation therapy for patients at high-risk of recurrence after radical prostatectomy: does timing matter? BJU Int. 2015 Nov; 116(5):713-20.
    View on PubMed
  3. Jalloh M, Leapman MS, Cowan JE, Shinohara K, Greene KL, Roach M, Chang AJ, Chan JM, Simko JP, Carroll PR. Patterns of Local Failure following Radiation Therapy for Prostate Cancer. J Urol. 2015 Oct; 194(4):977-82.
    View on PubMed
  4. Bossi A, Wiegel T, Roach M. Postprostatectomy Radiotherapy for Patients with High-risk Features on Definitive Pathology: A Plea for Evidence-based Medicine. Eur Urol. 2015 Nov; 68(5):775-6.
    View on PubMed
  5. Seymour ZA, Chang AJ, Zhang L, Kirby N, Descovich M, Roach M, Hsu IC, Gottschalk AR. Dose-volume analysis and the temporal nature of toxicity with stereotactic body radiation therapy for prostate cancer. Pract Radiat Oncol. 2015 Sep-Oct; 5(5):e465-72.
    View on PubMed
  6. Raleigh DR, Hsu IC, Braunstein S, Chang AJ, Simko JP, Roach M. Bladder wall recurrence of prostate cancer after high-dose-rate brachytherapy. Brachytherapy. 2015 Mar-Apr; 14(2):185-8.
    View on PubMed
  7. Hamstra DA, Bae K, Hanks G, Hu C, Shipley WU, Pan CC, Roach M, Lawton CA, Sandler HM. Impact of biochemical failure classification on clinical outcome: A secondary analysis of Radiation Therapy Oncology Group 9202 and 9413. Cancer. 2015 Mar 15; 121(6):844-52.
    View on PubMed
  8. Roach M. Natural History after Biochemical Failure Following Dose-escalated External Beam Radiation: An Opportunity to Improve Outcomes? Eur Urol. 2015 Jun; 67(6):1017-8.
    View on PubMed
  9. Ost P, Bossi A, Decaestecker K, De Meerleer G, Giannarini G, Karnes RJ, Roach M, Briganti A. Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature. Eur Urol. 2015 May; 67(5):852-63.
    View on PubMed
  10. Alexander J, Weinberg V, Gottschalk AR, Hsu IC, Shinohara K, Roach M. Pre-plan parameters predict post-implant D90 = 140 Gy for (125)I permanent prostate implants. J Contemp Brachytherapy. 2014 Jun; 6(2):143-53.
    View on PubMed
  11. Chen CP, Braunstein S, Mourad M, Hsu IC, Haas-Kogan D, Roach M, Fogh SE. Quality improvement of International Classification of Diseases, 9th revision, diagnosis coding in radiation oncology: Single-institution prospective study at University of California, San Francisco. Pract Radiat Oncol. 2015 Jan-Feb; 5(1):e45-51.
    View on PubMed
  12. Chang AJ, Autio KA, Roach M, Scher HI. High-risk prostate cancer-classification and therapy. Nat Rev Clin Oncol. 2014 Jun; 11(6):308-23.
    View on PubMed
  13. Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Kane CJ, Kawachi MH, Kuettel M, Kuzel TM, Lee RJ, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Raben D, Richey S, Roach M, Rohren E, Rosenfeld S, Schaeffer E, Small EJ, Sonpavde G, Srinivas S, Stein C, Strope SA, Tward J, Shead DA, Ho M. Prostate cancer, version 2.2014. J Natl Compr Canc Netw. 2014 May; 12(5):686-718.
    View on PubMed
  14. Roach M. Radium-223 vs EBRT for multiple painful bone metastases: is less more? Oncology (Williston Park). 2014 Apr; 28(4):297-8.
    View on PubMed
  15. Roach M. Radical prostatectomy v radiation: only a randomised trial can provide the answer. BMJ. 2014; 348:g2266.
    View on PubMed
  16. Garcia MM, Gottschalk AR, Brajtbord J, Konety BR, Meng MV, Roach M, Carroll PR. Endoscopic gold fiducial marker placement into the bladder wall to optimize radiotherapy targeting for bladder-preserving management of muscle-invasive bladder cancer: feasibility and initial outcomes. PLoS One. 2014; 9(3):e89754.
    View on PubMed
  17. Roach M. Current trends for the use of androgen deprivation therapy in conjunction with radiotherapy for patients with unfavorable intermediate-risk, high-risk, localized, and locally advanced prostate cancer. Cancer. 2014 Jun 1; 120(11):1620-9.
    View on PubMed
  18. Anwar M, Weinberg V, Chang AJ, Hsu IC, Roach M, Gottschalk A. Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir. Radiat Oncol. 2014; 9:42.
    View on PubMed
  19. Qi P, Pouliot J, Roach M, Xia P. Offline multiple adaptive planning strategy for concurrent irradiation of the prostate and pelvic lymph nodes. Med Phys. 2014 Feb; 41(2):021704.
    View on PubMed
  20. Anwar M, Westphalen AC, Jung AJ, Noworolski SM, Simko JP, Kurhanewicz J, Roach M, Carroll PR, Coakley FV. Role of endorectal MR imaging and MR spectroscopic imaging in defining treatable intraprostatic tumor foci in prostate cancer: quantitative analysis of imaging contour compared to whole-mount histopathology. Radiother Oncol. 2014 Feb; 110(2):303-8.
    View on PubMed

Go to UCSF Profiles, powered by CTSI